This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.

 

This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?
Paris
2024
Symposium

Date and time:

19.03.24 at 12:45-13:45 CET

Type:

Congress:
Speakers:

Welcome and introduction (10 min)

Barrier 1: Early evaluation and referral (20 min)

Barrier 1: Panel discussion (5min)

Barrier 2: Optimising cardiometabolic risk management (15 min)

Barrier 2: Panel discussion (5 min)

Summary and conclusion (5min)

properties.alt

Michael Roden

University Hospital Düsseldorf, Düsseldorf, Germany


Professor Roden is the Chair of Endocrinology and Metabolic Diseases and Director of the Division of Endocrinology and Diabetology and currently also head to the Department of Medical Clinics at Heinrich Heine University and University Hospital Düsseldorf. He is also CEO of the German Diabetes Center (DDZ), Düsseldorf, Germany and board member of the German Centers for Diabetes Research (DZD e. V.).

 

Professor Roden was trained at University of Vienna and Yale University. His clinical-translational studies address insulin resistance, energy metabolism addressing diabetes mellitus and related comorbidities, with a focus on metabolic dysfunction-associated steatotic liver diseases, specifically by using non-invasive technologies. He is a highly-cited researcher (2022, 2023 by Clarivate), has published 700+ peer-reviewed papers, received several international awards (e.g. Oskar-Minkowski Prize, G. B. Morgagni Prize-Gold Medal, Somogyi Award) and holds honorary doctorates of the Universities of Athens and Belgrade as well as a collaborative professorship at Kanasawa University, Japan. Professor Roden was Chairman of the EFSD, Executive Committee member of EASD, President of the Central European Diabetes Association, the Austrian Diabetes Association and Congress President of the German Diabetes Society. Appointed by the President of Germany, he also served as member of the German Council of Science and Humanities and its Head of the Committee Medicine.


Read full bio
properties.alt

Jerome Boursier

Université d’Angers, Angers, France


Jerome Boursier (MD, PhD) graduated from the Faculty of Medicine of Angers University, in 2006. In 2011, he presented his PhD entitled “Methodology to improve the accuracy of the non-invasive diagnosis of liver fibrosis in chronic hepatitis C”. In 2014, he completed a research fellowship in Anna Mae Diehl Lab in Duke University, investigating the area of the gut microbiota and MASLD. Jerome Boursier is Professor of Medicine Angers University since 2016 and is now the Head of the HIFIH Lab (UPRES 3859, SFR 4208) at Angers University, the Head of the Hepato-Gastroenterology Department at Angers University Hospital, and the General Secretary of the French Association for the Study of the Liver. Jerome Boursier has a long-standing expertise in natural history, diagnosis, and treatment of steatotic liver diseases, with a special interest in non-invasive tests of liver lesions (pathological significance, diagnostic and prognostic accuracy, disease monitoring, screening strategies). Initially in chronic viral hepatitis C and now in MASLD, he has contributed to the development and validation of several tests now widely used in clinical practice. He coordinates several research programs through national research projects, multicentre cohorts, and an international academic and industrial network. He is the author and co-authors of over 200 papers in international peer reviewed journals and has given over 150 faculty lectures.


Read full bio